Vesilind GW, Koepke JA, DesHarnais GR. Screening blood products for HTLV-I: what is the best approach?
TRANSFUSION SCIENCE 1989;
11:103-12. [PMID:
10149525 DOI:
10.1016/0955-3886(90)90017-d]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
A recent concern for disease transmission by blood transfusion is T-lymphotropic virus type I (HTLV-I). This virus is endemic in Japan, the Caribbean basin, subsaharan Africa, and, to a lesser extent, the southeastern United States and parts of Central and South America. HTLV-I, which has been shown to be transmitted via transfusion, is associated with adult T-cell leukemia (ATL) and certain degenerative neurological disorders. Antibodies to HTLV-I, an indicator of exposure to the virus, have been demonstrated in 0.025% of healthy U.S. donors. This study, using the Decision Tree Model, presents an approach to a donor screening policy which should be cost-effective and yet ensure a safe blood supply.
Collapse